The global cancer diagnostics market was valued at USD 23.84 Billion in 2024, driven by the rising prevalence of cancer and increasing awareness and early detection initiatives across the globe. The market is anticipated to grow at a CAGR of 11.50% during the forecast period of 2025-2034, with the values likely to reach USD 70.80 Billion by 2034.
Base Year
Historical Year
Forecast Year
Value in USD Billion
2025-2034
Cancer Diagnostics Market Outlook
*this image is indicative*
Cancer diagnostics involves identifying cancer early to improve treatment outcomes. It typically starts with a clinical evaluation, including physical exams and medical history reviews. Diagnostic tests like imaging (X-rays, CT scans, MRIs, PET scans) detect abnormalities, while blood tests identify cancer markers. Biopsies, where tissue samples are examined under a microscope, confirm malignancy and provide detailed information about the tumour. Advanced methods, such as molecular testing, identify genetic mutations to guide personalised treatments. Screening programmes, like mammograms and colonoscopies, help detect cancer in its early stages. Accurate diagnostics are essential for effective treatment planning and monitoring of disease progression.
Rising Merger and Acquisition Activities to Accelerate Market Growth
Increasing demand for specialised cancer diagnostics and expanding healthcare access in emerging regions are major drivers of growth in the market. For instance, in December 2024, Metropolis Healthcare Limited announced its acquisition of Core Diagnostics, based in Delhi NCR, for USD 29.62 million. This acquisition aims to strengthen Metropolis' cancer testing services and enhance its footprint across Northern and Eastern India. With Core Diagnostics’ extensive oncology portfolio and its established network of 200 cities, this move will drive market expansion and enhance diagnostic capabilities. The deal is set to propel Metropolis into a leading position, stimulating market growth in the forecast period by offering advanced cancer diagnostics to a wider demographic.
Increasing Fundings and Investments to Meet Rising Cancer Diagnostics Market Demand
Growing investments in innovative cancer therapies and advancements in radiotherapy are key drivers for the expanding market. For instance, in November 2024, ARC Innovation, part of Sheba Medical Center, secured USD 5.1 million in funding for Starget Pharma, a startup developing targeted radioligand therapies for precise cancer diagnosis and treatment. With funding from the Cancer Focus fund, supported by MD Anderson Cancer Center, Starget Pharma plans to conduct clinical trials on cancers such as sarcomas and melanoma. This breakthrough in cancer diagnostics and treatment will likely enhance the efficacy of therapies and offer new diagnostic tools, positioning this technology to significantly impact the global market in the forecast period.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Cancer Diagnostics Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Technology
Market Breakup by Indication
Market Breakup by Clinical Positioning
Market Breakup by Region
Molecular Diagnostics to Lead Market Breakup by Technology
Molecular diagnostics is expected to hold a major market share by technology, driven by advanced technologies like DNA sequencing, PCR, and cfDNA testing. As per the analysis by Expert Market Research, the global molecular diagnostics market is expected to grow at a CAGR of 8.2% during the forecast period of 2025-2034. The growing need for personalised treatment and early detection of cancer, along with the demand for more accurate and less invasive diagnostic methods, is fuelling the expansion of this segment. Molecular diagnostics offers high sensitivity and specificity, making it essential in identifying cancer at its earliest stages. With continuous advancements in genomics and biomarker discovery, this segment is expected to see substantial growth during the forecast period, revolutionising cancer detection.
Cancer Diagnostics Market Segmentation by Application to Undergo Significant Growth
Breast cancer will likely hold a substantial market share due to its high incidence and ongoing advancements in diagnostic technologies. As the most common cancer among women globally, the demand for early detection and personalised treatment plans has led to a surge in diagnostic solutions for breast cancer. As per the analysis by Expert Market Research, the global breast cancer treatment market is likely to grow at a CAGR of 10.10% during the forecast period of 2025-2034. Innovations in imaging technologies, along with molecular diagnostics, have significantly improved detection accuracy and outcomes. This segment’s dominant share is poised to continue its growth due to increasing awareness, early screening initiatives, and the rising number of breast cancer cases worldwide, ensuring sustained market demand in the coming years.
Cancer Diagnostics Market by Clinical Positioning to Witness Growth
Early detection is expected to hold a considerable share in the clinical positioning sector, owing to its critical role in improving patient outcomes and survival rates. With increasing awareness about the benefits of diagnosing cancer in its early stages, both patients and healthcare providers are prioritizing screening methods. Advancements in imaging and molecular diagnostics have enabled more accurate and timely detection, making it a vital area for market growth. As healthcare systems globally focus on preventive care and early-stage cancer detection, this segment is expected to dominate the market in the forecast period, supporting the global demand for innovative diagnostic tools.
North America is expected to hold a major share of the market driven by the region's advanced healthcare infrastructure, high investment in research and development, and increasing cancer incidence rates. The U.S., in particular, benefits from robust healthcare policies, early screening programmes, and access to cutting-edge diagnostic technologies. A strong presence of leading healthcare companies and continuous advancements in molecular diagnostics and imaging technologies further bolster the market. Additionally, the growing focus on personalised medicine and precision oncology, combined with high awareness and well-established insurance systems, supports rapid adoption of cancer diagnostics in North America, positioning it for sustained market leadership in the forecast period.
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Headquartered in Basel, Switzerland, F. Hoffmann-La Roche AG was established in 1896. It is a global leader in diagnostics and healthcare, offering a wide range of products in oncology diagnostics. Their portfolio includes innovative diagnostic tests for cancer biomarkers, molecular diagnostics, and liquid biopsy tests, aimed at improving early detection and treatment monitoring. In September 2024, Roche announced the expansion of its digital pathology open environment, incorporating over 20 AI algorithms from eight new collaborators. These partnerships aim to optimise the diagnostic process by assisting pathologists and researchers in detecting and diagnosing cancers more accurately. The integration of AI technologies will accelerate diagnostic workflows, improve detection rates, and increase precision in cancer diagnosis. Roche’s oncology diagnostics solutions are crucial in personalised medicine, enabling healthcare providers to tailor treatments based on individual patient needs, thereby enhancing patient outcomes and advancing cancer care.
Founded in 1956 and headquartered in Waltham, Massachusetts, Thermo Fisher Scientific, Inc. is a major player in the global diagnostics market. The company’s portfolio in cancer diagnostics includes advanced molecular diagnostics, next-generation sequencing (NGS) solutions, and laboratory instruments. These innovations support early detection, disease monitoring, and targeted treatment in oncology. Thermo Fisher's products empower researchers and clinicians to better understand cancer’s genetic profile, enabling the development of personalised therapies and improving patient care. Their broad range of tools plays a key role in advancing global cancer research and diagnostics.
Becton, Dickinson and Company (BD) was founded in 1897 and is headquartered in Franklin Lakes, New Jersey. BD provides comprehensive solutions in the cancer diagnostics sector, specialising in precision diagnostics, molecular testing, and flow cytometry. Their portfolio includes diagnostic instruments, reagents, and systems for oncology, enabling faster, more accurate detection and monitoring of cancer. BD's products aid in assessing tumour biomarkers, supporting both clinical and research applications. Their innovative approach is focused on enhancing diagnostic workflows and improving the accuracy of cancer detection and prognosis.
Danaher Corporation, established in 1969 and headquartered in Washington, D.C., is a global science and technology innovator. In the cancer diagnostics market, Danaher’s portfolio includes diagnostic instruments, imaging solutions, and advanced molecular testing platforms. Its brands, such as Cepheid and Leica Biosystems, provide cutting-edge diagnostic technologies, enabling clinicians to detect cancer early and monitor treatment efficacy. With a focus on precision and efficiency, Danaher's innovations enhance oncology care by offering faster, more accurate diagnostic tools, ultimately supporting personalised cancer therapies and improving patient outcomes.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Agilent Technologies Inc., GE Healthcare, Abbott, Siemens Healthineers, Bio-Rad Laboratories, Inc., Illumina, Inc., PerkinElmer Inc., QIAGEN, Hologic, Inc., Myriad Genetics, Inc., Sysmex Corporation, NeoGenomics Laboratories, Inc., Foundation Medicine, Grail, Guardant, Tempus, Delfi Diagnotics, and Exact Sciences Corporation.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Technology |
|
| Breakup by Indication |
|
| Breakup by Clinical Positioning |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share